Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

flash9875 May. 7 at 2:33 PM

$HROW when will the violence end…perhaps Monday….

0 · Reply

Finnish_boy May. 7 at 1:09 PM

$HROW Indexes are going much much higher. HROW will hit $100 by June 2027. We are going to make tons of money. TARS reported Q1 earnings for their dry eye drug. Little lower than consensus. I didnt find QoQ Rx growth. TMDX dropped to 70s. Not so familiar about the risks and competition but i think it's great buy now!

0 · Reply

flash9875 May. 7 at 11:49 AM

$HROW partly sunny skies bring sun lotion and an umbrella…perfect weather for a party

0 · Reply

Finnish_boy May. 7 at 11:24 AM

$HROW Byqlovi launch, Byooviz launch, Iheezo retina data. Nice momentum ahead. If Q1 revenue over 55M, i think SP goes up. If near consensus of 52.5M, then SP flat or down. I think we dont see 20s, SP can drop to $35 easily though. If they do some acquisition, then SP can go up anyways. But acquistition unlikely. And if they adjust guidance 10M higher, SP goes up. But very unlikely. Anyways, i am afraid to buy before earnings. I buy after earnings. If they pull the rabbit out of the hat and SP goes up 30%, i will buy anyways i dont care bc SP is going to $100 in 1-2 years anyways. Lets see the earnings. I will comment after earnings something when i have already loaded all i can.

2 · Reply

Tennis_4567 May. 6 at 8:29 PM

$HROW

2 · Reply

flash9875 May. 6 at 2:17 PM

$HROW Baum will have to show his love first….thats where we are at…

0 · Reply

Finnish_boy May. 5 at 10:13 PM

$HROW The race is who hits $100 first. Harrow wins. Watch it.

0 · Reply

bryantboy99 May. 5 at 2:27 PM

$ETON she's gonna catch $HROW before much longer

0 · Reply

HROW200 May. 5 at 8:46 AM

$HROW If there is going to be a press release before quarterly earnings report, I’m thinking Tuesday, Wednesday, or Thursday this week.

2 · Reply

Dbarnyard May. 4 at 6:06 PM

$HROW Wow, had HROW held on to its shares of $ETON, what would that stake be worth today? $100M? $125M? Crazy...

2 · Reply

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Apr 16, 2026, 7:00 AM EDT - 21 days ago

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Apr 14, 2026, 10:30 AM EDT - 23 days ago

LogiCare3PL Selected as Distribution Partner by Harrow

Mar 24, 2026, 4:57 PM EDT - 6 weeks ago

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

Mar 24, 2026, 8:15 AM EDT - 6 weeks ago

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Mar 18, 2026, 7:00 AM EDT - 7 weeks ago

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Harrow Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 9:07 AM EST - 2 months ago

These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Mar 4, 2026, 7:00 AM EST - 2 months ago

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

Harrow Earnings Call Transcript: Q4 2025

Mar 3, 2026, 7:00 AM EST - 2 months ago

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Mar 2, 2026, 4:05 PM EST - 2 months ago

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Feb 18, 2026, 7:00 AM EST - 2 months ago

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Feb 17, 2026, 7:00 AM EST - 2 months ago

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Feb 2, 2026, 7:00 AM EST - 3 months ago

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Dec 2, 2025, 3:00 PM EST - 5 months ago

Harrow Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 5 months ago

Harrow to Present at Two Investor Conferences in December

Nov 18, 2025, 7:00 AM EST - 6 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 11, 2025, 8:00 AM EST - 6 months ago

Harrow Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:05 PM EST - 6 months ago

Harrow Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 6, 2025, 7:00 AM EDT - 7 months ago

ImprimisRx Announces Leadership Changes

Sep 26, 2025, 11:30 AM EDT - 7 months ago

Harrow Transcript: Investor Day 2025

Sep 26, 2025, 7:00 AM EDT - 7 months ago

Harrow to Acquire Melt Pharmaceuticals

Sep 25, 2025, 4:05 PM EDT - 7 months ago

Harrow Launches Harrow Access for All (HAFA)

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 8, 2025, 5:57 PM EDT - 8 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Aug 13, 2025, 8:30 AM EDT - 9 months ago

Harrow Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Harrow Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 9 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Jul 29, 2025, 7:00 AM EDT - 10 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 15, 2025, 10:38 AM EDT - 10 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jun 18, 2025, 7:00 AM EDT - 11 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 9, 2025, 7:00 AM EDT - 11 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

May 14, 2025, 7:00 AM EDT - 1 year ago

Harrow to Present at Two Investor Conferences in May

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q1 2025

May 8, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces First-Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 1 year ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Apr 24, 2025, 10:00 AM EDT - 1 year ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 10:45 AM EDT - 1 year ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Harrow Launches VEVYE® Access for All

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 3, 2025, 7:15 AM EST - 1 year ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Jan 27, 2025, 7:30 AM EST - 1 year ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Jan 7, 2025, 7:00 AM EST - 1 year ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Dec 4, 2024, 8:00 AM EST - 1 year ago

Harrow Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 7:00 AM EST - 1 year ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 15, 2024, 7:00 AM EST - 1 year ago

Harrow Announces Participation in Upcoming Investor Conferences

flash9875 May. 7 at 2:33 PM

$HROW when will the violence end…perhaps Monday….

0 · Reply

Finnish_boy May. 7 at 1:09 PM

0 · Reply

flash9875 May. 7 at 11:49 AM

$HROW partly sunny skies bring sun lotion and an umbrella…perfect weather for a party

0 · Reply

Finnish_boy May. 7 at 11:24 AM

2 · Reply

Tennis_4567 May. 6 at 8:29 PM

$HROW

2 · Reply

flash9875 May. 6 at 2:17 PM

$HROW Baum will have to show his love first….thats where we are at…

0 · Reply

Finnish_boy May. 5 at 10:13 PM

$HROW The race is who hits $100 first. Harrow wins. Watch it.

0 · Reply

bryantboy99 May. 5 at 2:27 PM

$ETON she's gonna catch $HROW before much longer

0 · Reply

HROW200 May. 5 at 8:46 AM

$HROW If there is going to be a press release before quarterly earnings report, I’m thinking Tuesday, Wednesday, or Thursday this week.

2 · Reply

Dbarnyard May. 4 at 6:06 PM

$HROW Wow, had HROW held on to its shares of $ETON, what would that stake be worth today? $100M? $125M? Crazy...

2 · Reply

Finnish_boy May. 4 at 4:27 PM

$HROW

0 · Reply

Finnish_boy May. 4 at 4:09 PM

$HROW One week waiting anymore and then bull run finally starts. I expect drop to $35 after earnings and then recovering within couple of weeks to over $40 levels. And within a year to $100. It not what markets have priced in, it's just another round of manipulation. My revenue guess is 52m. ( Analyst consensus) I have no idea.

0 · Reply

S144 May. 4 at 10:00 AM

$HROW 2026 revenue guidance: $357.5M versus 2025 revenue $272M . So expected growth: +31.4% Harrow (HROW) To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026: https://www.harrow.com/news-releases/news-release-details/harrow-report-first-quarter-2026-financial-results-after-market I think there is a good chance Q1 results will be good. I am buying this week ..

0 · Reply

Thelonius_Stonk May. 1 at 11:07 AM

$HROW ripe

1 · Reply

BillionerOfKing May. 1 at 4:56 AM

$HROW Current Stock Price: $40.53 Contracts to trade: $41.0 HROW May 15 2026 Call Entry: $2.07 Exit: $3.82 ROI: 84% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

flash9875 Apr. 30 at 11:02 PM

$HROW Bloomberg 1 to base…please transmit now

0 · Reply

Stacks_Edwards Apr. 30 at 10:20 PM

$HROW powering up for 45 before earnings

0 · Reply

Finnish_boy Apr. 29 at 10:47 PM

$HROW Make sure you have enough stocks for next 1-2 years. Great stocks will absolutely fly, doesnt matter what great stocks you own, make sure AI cant disturb them totally. My picks: HROW (revenue growth >30%, ridiculous valuation, easy 2x) CIFR (data center megahouse, easy 2x) IREN (same as CIFR) NRXS (most less risky medtech ramp up play, easy 2x) PYPD (never seen better setup, totally under radar, easy 2x) HITI (buy in H2, H1 can be lame, most manipulated stock, easy 2x) AI is not threat for any of these. I like also TMDX under $100. That's also easy money. I WILL MAKE TONS OF MONEY. LETS GO.

1 · Reply

Finnish_boy Apr. 29 at 10:27 PM

$HROW Silent board. I have tried to post less also. I will buy very heavily HROW after Q1 earnings. I gather 50% weight on my portfolio. Indexes will go much higher. People dont understand how revolutionary years are ahead. AI boom is massive. Remember when i told that google will be monster. Up nicely after earnings over ATH levels . BUCKLE UP ! Also, HROW $100 in a year. LETS RIDE.🤑

1 · Reply

flash9875 Apr. 29 at 4:14 PM

$HROW who flushed the toilet...

0 · Reply

SuperGreenToday Apr. 29 at 12:10 AM

$HROW Share Price: $40.49 Contract Selected: Oct 16, 2026 $40 Calls Buy Zone: $6.03 – $7.46 Target Zone: $11.46 – $14.01 Potential Upside: 79% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	1.51B
Revenue (ttm)	272.30M
Net Income (ttm)	-5.14M
EPS (ttm)	N/A
PE Ratio	89.33
Forward PE	83.06
Profit Margin	-1.89%
Debt to Equity Ratio	4.67

Volume	713,000
Avg Vol	756,350
Day's Range	N/A - N/A
Shares Out	37.27M
Stochastic %K	61%
Beta	0.34
Analysts	Strong Sell
Price Target	$66.71